Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study
作者： Marten A. Lantinga , , Hedwig M. A. D’Agnolo , Niek F. Casteleijn , Johan W. de Fijter
DOI: 10.1007/S40264-016-0486-X
关键词:
摘要: Introduction and Aims The DIPAK-1 Study investigates the reno- hepatoprotective efficacy of somatostatin analog lanreotide compared with standard care in patients later stage autosomal dominant polycystic kidney disease (ADPKD). During this trial, we witnessed several episodes hepatic cyst infection, all during treatment. We describe these events provide a review literature.
ru.nl
springer.com
core.ac.uk
narcis.nl参考文章(33)
Frederik Temmerman, Thien Ahn Ho, Ragna Vanslembrouck, Walter Coudyzer, Jaak Billen, Fabienne Dobbels, Jos van Pelt, Bert Bammens, Yves Pirson, Frederik Nevens, Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease Clinical Gastroenterology and Hepatology. ,vol. 13, pp. 2353- 2359.e1 ,(2015) , 10.1016/J.CGH.2015.05.039
Loes Van Keimpema, Daan B. De Koning, Bart Van Hoek, Aad P. Van Den Berg, Martijn G. H. Van Oijen, Robert A. De Man, Frederik Nevens, Joost P. H. Drenth, Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver International. ,vol. 31, pp. 92- 98 ,(2011) , 10.1111/J.1478-3231.2010.02247.X
Titus F. M. Wijnands, Myrte K. Neijenhuis, Wietske Kievit, Frederik Nevens, Marie C. Hogan, Vicente E. Torres, Tom J. G. Gevers, Joost P. H. Drenth, Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver International. ,vol. 34, pp. 1578- 1583 ,(2014) , 10.1111/LIV.12430
S. Treille, J.M. Bailly, J. Van Cauter, F. Dehout, B. Guillaume, The Use of Lanreotide in Polycystic Kidney Disease: A Single-Centre Experience Case reports in nephrology. ,vol. 4, pp. 18- 24 ,(2014) , 10.1159/000358268
Melissa Chrispijn, Tom J.G. Gevers, Jeroen C. Hol, Rene Monshouwer, Heleen M. Dekker, Joost P.H. Drenth, Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. Journal of Hepatology. ,vol. 59, pp. 153- 159 ,(2013) , 10.1016/J.JHEP.2013.03.004
Marion Sallée, Cédric Rafat, Jean-Ralph Zahar, Benoît Paulmier, Jean-Pierre Grünfeld, Bertrand Knebelmann, Fadi Fakhouri, Cyst Infections in Patients with Autosomal Dominant Polycystic Kidney Disease Clinical Journal of The American Society of Nephrology. ,vol. 4, pp. 1183- 1189 ,(2009) , 10.2215/CJN.01870309
T. Suwabe, H. Araoka, Y. Ubara, K. Kikuchi, R. Hazue, K. Mise, S. Hamanoue, T. Ueno, K. Sumida, N. Hayami, J. Hoshino, A. Imafuku, M. Kawada, R. Hiramatsu, E. Hasegawa, N. Sawa, K. Takaichi, Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics European Journal of Clinical Microbiology & Infectious Diseases. ,vol. 34, pp. 1369- 1379 ,(2015) , 10.1007/S10096-015-2361-6
Tom J. G. Gevers, Joost P. H. Drenth, Diagnosis and management of polycystic liver disease Nature Reviews Gastroenterology & Hepatology. ,vol. 10, pp. 101- 108 ,(2013) , 10.1038/NRGASTRO.2012.254
Marten A. Lantinga, Ruud G.L. de Sévaux, Joost P.H. Drenth, 18F-FDG PET/CT during diagnosis and follow-up of recurrent hepatic cyst infection in autosomal dominant polycystic kidney disease. Clinical Nephrology. ,vol. 84, pp. 61- 64 ,(2015) , 10.5414/CN108495
Eugene D. Jackson, Physiology of the Splanchnic Circulation. Archives of Internal Medicine. ,vol. 118, pp. 291- 1281 ,(1966) , 10.1001/ARCHINTE.1966.00290150105030